|
Gad Berdugo
Managing Partner
EXPLORIUM CAPITAL LLC
New York City
USA
|
Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Strategic Advisor to Nutcracker Therapeutics, a company developing a groundbreaking “mRNA on a biochip” platform, as Executive-In-residence at Columbia Technology Ventures and as Vice Chairman of the Board of Directors of clinical stage precision oncology company, Evexta Bio. In 2022, Mr. Berdugo co-founded a targeted mRNA-LNP based venture focusing on in vivo gene editing. Mr. Berdugo brings over 30 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter’s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London,